About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Toyama Chemical Signs Agreement With TR- Pharm on Iguratimod

by Bidita Debnath on October 15, 2015 at 2:24 AM
Font : A-A+

 Toyama Chemical Signs Agreement With TR- Pharm on Iguratimod

Recently, Fuji film Group company Toyama Chemical Co. Ltd signed a licensing agreement with TR- Pharm, a Turkey based company. The agreement aims at developing, manufacturing and marketing pharmaceuticals, concerning Toyama Chemical's rheumatoid arthritis drug "iguratimod".

Iguratimod is a drug for treating rheumatoid arthritis, jointly developed with Eisai Co., Ltd. It was approved for manufacturing and marketing in Japan on June 29, 2012, and launched in the domestic market in September 2015.

Advertisement

Iguratimod is an oral drug that underwent domestic clinical trials in combination with methotrexate, the standard care for rheumatoid arthritis, and became the first agent in Japan that demonstrated efficacy when administered in combination with MTX on rheumatoid arthritis patients. Iguratimod is a drug that provides a new treatment option for rheumatoid arthritis.

The new licensing partner TR-Pharm is an affiliate of Russia's powerful pharmaceutical company R-Pharm. TR-Pharm has been established as a development and manufacturing base for Turkey, Middle East and North Africa. TR-Pharm has over 10 agents in development pipeline, focusing on the field of oncology, virology and inflammatory diseases for business expansion.
Advertisement

Under the licensing agreement, Toyama Chemical provides TR-Pharm with the exclusive rights for developing, manufacturing and marketing iguratimod for the treatment of rheumatoid arthritis in Turkey, Middle East and North Africa, in exchange for a lump-sum payment and royalty. Toyama Chemical, a subsidiary of Fujifilm holdings Corporation, specializes in pharmaceutical research and development, and strives to contribute to further development of global health care through new drug development.

Source: ANI
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Advertisement
News Category
What's New on Medindia
Black Tea Protects against Blood Pressure and Heart Diseases
Green Mediterranean Diet may Help Repair Age-Related Brain Damages
Cervical Cancer Awareness Month 2022
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.


Recommended Reading
Indian Government May Bar Pharmaceuticals from Giving Gifts to Doctors
The Department of Pharmaceuticals has prepared the Uniform Code of Pharmaceuticals Marketing ......
Glenmark Pharmaceuticals Restrained from Selling Its Type-2 Diabetes Drug
Glenmark has infringed Merck's product which contained sitagliptin phosphate monohydrate - an ......
2 Indian-Based Pharmaceuticals Recall Their Drugs From The US Market
Sun Pharma initiated recall of Bupropion Hydrochloride Extended-release Tablets USP (SR) while ......
USFDA Approval Awaited By Glenmark Pharmaceuticals For 4-6 Products During This Year
The company had already got approvals for 8 products this year and awaits approval of 4-6 products ....

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2022

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use
open close
ASK A DOCTOR ONLINE
I have read and I do accept terms of use - Telemedicine

Advantage Medindia: FREE subscription for 'Personalised Health & Wellness website with consultation' (Value Rs.300/-)